Is Thymosin Alpha-1 Legal in California? How to Access It Legally
At a glance
- FDA approval / None in the US; four orphan drug designations, which are not approvals [1]
- FDA list, state-licensed pharmacies / In none of the three categories (updated May 14, 2026); category 1 policy does not apply [2]
- FDA list, outsourcing facilities / Category 3, 'nominated without adequate support' (updated March 21, 2025) [3]
- Advisory committee vote / 4 yes, 17 no, no abstentions, December 4, 2024 [4]
- HHS draft peptide policy / Not among the six listed peptides, October 2026 [5]
- Approved as a medicine elsewhere / Italy, India and Hong Kong, as thymalfasin (Zadaxin) [1]
What the federal position is
Drugs@FDA has no application for thymosin alpha-1, so it is not approved in the US; its four US orphan drug designations come through a separate process and are not an approval [1]. State-licensed pharmacies compound for an identified patient with a valid prescription; registered outsourcing facilities follow cGMP rules and may also compound for office stock on a facility's order [6].
On FDA's list for state-licensed pharmacies, nominated substances fall in three categories. Thymosin alpha-1 is in none of the three (updated May 14, 2026), so FDA's category 1 policy — generally no action against compounders who meet the conditions — does not apply [2]. On the list for outsourcing facilities (updated March 21, 2025) it is category 3, 'nominated without adequate support' [3].
FDA proposed that it not be added to the pharmacy bulks list, and on December 4, 2024 its Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate; members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. It is also not one of the six peptides in HHS's October 2026 draft policy [5].
FDA's posted safety concerns
Thymosin alpha-1 had been in category 2 — substances FDA identified as presenting significant safety risks — and moved to the nominated-but-withdrawn table when the nominators withdrew [7]. FDA's stated concerns remain posted: 'significant risk for immunogenicity for certain routes of administration', peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [7].
Approved elsewhere, and the dose on that label
Italy authorizes Zadaxin as an adjuvant to influenza vaccination in immunocompromised people; India approves it for chronic hepatitis B in adults 18 or older with compensated liver disease and virus replication; Hong Kong also authorizes it [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, which is not a marketing approval [1].
There is no US-approved dose. The Italian label gives 1.6 mg subcutaneously or intramuscularly twice weekly for 4 weeks from the first vaccination, repeated from week 8 to week 12 at the second, and says not for children, contraindicated in pregnancy and breastfeeding, with caution for people who have allergies or autoimmune disease or who take other immune-modulating drugs [1]. Zadaxin is a finished injection and is not interchangeable with bulk thymosin alpha-1 powder [1].
Frequently asked questions
Is thymosin alpha-1 FDA-approved?
Can a pharmacy compound thymosin alpha-1?
What did FDA's advisory committee say?
Is there a US-approved thymosin alpha-1 dose?
References